TheraRadar
← Back
Data updated: Jul 17, 2026

LABORATORIOS GRIFOLS

Generics
Pharmaceuticals Execution: Fair

LABORATORIOS GRIFOLS is a generic drug manufacturer with 1 FDA-approved products.

2017
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

LABORATORIOS GRIFOLS at a Glance

  • Fast trial execution (31 months median completion)

LABORATORIOS GRIFOLS's Key Drugs

LABORATORIOS GRIFOLS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

LABORATORIOS GRIFOLS's Recent FDA Approvals

New NDA/BLA approvals for LABORATORIOS GRIFOLS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

LABORATORIOS GRIFOLS's Therapeutic Areas

Disease areas where LABORATORIOS GRIFOLS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

LABORATORIOS GRIFOLS Pipeline Snapshot

Active clinical trials for LABORATORIOS GRIFOLS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 5/13 completed
  • • Speed: 31 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges